Absci (ABSI) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed MaxCyte (MXCT) over the past year, gaining 146.5% versus a loss of 32.9%. Over five years, ABSI leads with a -13.3% price change compared with -90.6% for MXCT. Absci is the larger company by market cap ($1.57 billion vs $103.7 million), about 15.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | MXCT |
|---|---|---|
| Share price | $9.12 | $1.01 |
| Market cap | $1.57B | $103.72M |
| 1-day change | -1.08% | -3.37% |
| YTD return | +164.18% | -32.90% |
| 1-year return | +146.52% | -32.90% |
| 5-year return | -13.26% | -90.57% |
| EPS (TTM) | $-0.79 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $1.87 |
| 52-week low | $2.24 | $0.643 |
| Distance from 52-week high | -24.35% | -46.11% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +57.89% | — |
| Average volume | 3.45M | 685.34K |
| Shares outstanding | 171.61M | 103.21M |
| Employees | 140 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Absci is about 15.1 times larger than MaxCyte by market value ($1.57B vs $103.72M).
- ABSI has outperformed MXCT by 179.4 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
ABSI vs MXCT FAQ
Which is bigger, Absci or MaxCyte?
Absci (ABSI) is larger, with a market capitalization of $1.57B compared with $103.72M for MaxCyte (MXCT).
Which stock has performed better over the past year, ABSI or MXCT?
ABSI returned +146.52% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are Absci and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.